Bio­gen and Io­n­is aban­don ALS drug af­ter dis­ap­point­ing ear­ly-stage tri­al

Bio­gen and Io­n­is are drop­ping an ex­per­i­men­tal treat­ment for amy­otroph­ic lat­er­al scle­ro­sis, or ALS, a neu­rode­gen­er­a­tive dis­ease in which peo­ple lose mus­cle con­trol over time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.